May 2023

Celix Pharma announces the launch of Vecit® MR tablets (Solifenacin / Tamsulosin) 

Celix Pharma is pleased to announce the launch of Vecit® 6mg / 0.4 mg Modified-release Tablets (Solifenacin / Tamsulosin) on loss of market exclusivity for Vesomni® in the UK. Vecit® MR tablets are supplied in blister (patient) packs containing 30 tablets. 

Vecit® is indicated in the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy. Vecit® is a fixed dose combination containing two active substances, solifenacin and tamsulosin. These drugs have independent and complementary mechanisms of action in the treatment of lower urinary tract symptoms (LUTS) associated with BPH.

Tamsulosin belongs to a group of medicines called alpha blockers which helps to reduce the symptoms of an enlarged prostate by relaxing the muscle around the bladder and prostate gland(1).  Solifenacin is a selective muscarinic receptor antagonist which works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder(2). 

Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Another important day 1 launch for Celix Pharma. This is our second product within the Urology / OAB space as we continue to add products to our portfolio with none or limited generic alternatives in the UK.” 

Shantreddy, Co-founder & COO added, “Happy to bring another complex development product to market on day 1.”

Source:

1 NHS UK (www.nhs.uk/medicines/tamsulosin/about-tamsulosin/)

2  Kim Chilman-Blair, J L H R Bosch, 2004, Solifenacin: treatment of overactive bladder, , Drugs Today (Barc),  Apr;40(4):343-53